ClinicalTrials.gg
RecruitingNCT06346444BIRSUpdated Apr 4, 2024

Biomarkers in Rett Syndrome

An observational study in Rett Syndrome, sponsored by IRCCS Fondazione Stella Maris. Recruiting at 4 sites in 2 countries. Open to female participants aged 0 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by IRCCS Fondazione Stella Maris · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
0 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Rett Syndrome with a site in Italy — 3 open to participants now, 3 under way, 1 of them phase 3. Rett Syndrome · Italy.

Started
2020
with 1 other
Observational
2 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
IRCCS Fondazione Stella Maris

Among the 11 studies in Rett Syndrome with a site in Italy, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 10th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

3 of the 11 studies in Rett Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 0 Years to 18 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Rett Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Rett syndrome (RTT) is an X-linked genetic disorder that causes severe neurological development disorder. In its classic form, it seems to affect almost exclusively females with an incidence of up to one in 10,000 females. Patients affected by Rett Syndrome can present a wide range of symptoms, in different combinations and of varying intensity, such as slowed growth of head circumference, abnormalities in walking and balance, loss of functional use of the hands often replaced by repetitive and stereotyped hand movements like "hand washing", loss of communicative-relational skills including expressive language, epilepsy, breathing abnormalities, and osteo-muscular alterations. In light of the growing potential of clinical therapies, identification and early diagnosis are considered essential. Many disease modification strategies have been achieved through translational research studies and clinical trials that have allowed the recognition of the most effective therapeutic and clinical interventions to date.

This study arises from the need to advance in the understanding of the pathogenesis of RTT through a multicentric collaboration in order to (a) identify early biomarkers of RTT (b) delve into the alterations of interconnectivity, crucial for understanding the loss of motor functions and language through systematic collection of anamnestic, genetic, and clinical-instrumental data. The aim is to provide a valuable contribution to the study of the clinical phenotype of Rett and the identification of early interventions.

Read the detailed description

The study aims to collect and analyze clinical-instrumental data from patients affected by Rett Syndrome through a prolonged monitoring program aimed at identifying disease biomarkers.

The study is a prospective observational type, with multicentric enrollment (IRCCS Stella Maris, AOU Meyer, Versilia Hospital Regional Reference Center for Rett Syndrome-USL Toscana Nord-Ovest), non-profit. New diagnosis patients and patients already included in the databases of each center will be enrolled. The cohort observational study will be completed, where possible, by a case-control study that involves the enrollment of siblings of the proband included in the study cohort.

Data regarding the registration of brain electrical activity through EEG of both the cohort and the patients' siblings, and acquisitions through Eye Tracker of the patients only, will be analyzed by Dr. Daniela Tropea's study group at Trinity College Dublin (Genetic Neuropsychiatry and Neuroscience Institute).

The study is expected to start immediately after the approval of the protocol by this Ethics Committee.

The study is expected to last four years. The study involves the enrollment of every case of Rett syndrome in the developmental age attending one of the Italian centers and an annual follow-up with clinical and instrumental controls provided by a dedicated path.

Sample Size The sample size has been estimated according to the syndrome's prevalence in the general population and based on the number of retrospective patient samples affected by Rett Syndrome.

The study plans to enroll approximately 100 patients consecutively, according to a pre-established schedule that includes observations and evaluations provided by the protocol.

FOLLOW-UP PROCEDURE The follow-up of each patient will be carried out annually through clinical monitoring and instrumental application of what is listed in the primary endpoint except for the brain MRI, whose repetition if necessary will be agreed upon based on the evolution of the clinical picture.

DEFINITION OF STUDY CONCLUSION The end of the monitoring of patients is expected upon reaching the age of 18 years.

DATA MANAGEMENT For each recruited patient, after deliberation through informed consent, data contained within the clinical record will be collected. At recruitment, data related to diagnosis, gestational age at birth, auxological parameters at birth, Apgar score, main clinical anamnestic data related to the perinatal period, and outcome of neuroimaging assessments carried out (for example, brain MRI, transfontanellar cerebral ultrasound) will be acquired and recorded in a specific database.

To protect privacy, each patient will be assigned a numeric code, therefore the database will not contain any demographic data, and access will be protected by a password and limited to personnel involved in the study only. The database will be progressively implemented with the outcomes of the assessments, acquired systematically, according to the correspondence code of the individual subject. The EEG video recording data will be accessible from the clinical documentation and coded systematically. The EEG data and the acquisitions through Eye Tracker obtained in the Italian enrollment centers will be analyzed at Trinity College Dublin in an anonymous manner through identification by numeric code and only after signed consent from the parents.

DATA CONSERVATION The data managers and the measures of anonymization will be the responsibility of the main experimenters of the study. All data will be stored in secure places and on password-protected files, at the patient's home institute.

ETHICAL CONSIDERATIONS The study conforms to the ethical principles recognized for clinical experimentation, to the principles of good clinical practice.

The protocol has been submitted for approval to the ethical committee and/or competent authority.

ACQUISITION OF INFORMED CONSENT AND DATA PROCESSING At the time of the direct interview with the families, a detailed explanation will be provided orally and a written informative note (which will remain with the parents). The importance of the study and the data used for the purposes of our study will also be explained, specifying the request for release for the compilation of the database, however under an identification code.

The paper documents related to informed consent will be handed over to the family so that they can be read and understood in their entirety and retrieved following a subsequent interview in which the parents can ask clarifying questions and definitively confirm their consent to the study.

03

Conditions studied

  • Rett Syndrome

Browse trials for

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The sample size has been estimated according to the syndrome's prevalence in the general population and based on the number of retrospective patient samples affected by Rett Syndrome and Reti-like Syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects aged between 0 and 18 years with Rett Syndrome, classic (mutation of the MECP2 gene) and Rett variants (CDKL5, FOXG1 mutations, and other MECP2 mutations), genetically confirmed:

    • newly diagnosed
    • previously diagnosed if possessing data recorded and stored in the enrollment centers' records;
    • upon written from the parents.
  • Siblings of the probands of any age who will undergo EEG registration will also be enrolled.

Exclusion criteria

Exclusion Criteria:

  • Patients with Rett Syndrome presenting a compromise in the general health status to such an extent that it makes it impossible to apply the clinical-instrumental evaluation and monitoring tools used for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes

Interventions

  • OtherDiagnostic test and behavioral

    Questionnaires (CGI, RSBQ) and Outcome measurements (Neuroscope, EEG, Brain MRI, Bone densitometry, X-ray of thoracic and lumbosacral spine Blood biomarkers-RNA, proteins, other metabolites-)

06

What researchers measure

Primary outcomes

  1. Age at diagnosis

    Time frame: every year for four years

  2. Mutation in MECP2

    Number of different single variant

    Time frame: every year for four years

  3. Neuroscope alterations

    NeuroScope is an advanced viewer for neurophysiological and behavioral data: it can display local field potentials (LFPs), neuronal spikes and behavioral events.

    Time frame: every year for four years

  4. Electroencephalogram (EEG) alterations

    Time frame: every year for four years

  5. Brain magnetic resonance imaging (MRI) alteration

    Time frame: every year for four years

  6. Bone densitometry alterations

    Time frame: every year for four years

  7. Thoracic radiographic alterations

    Time frame: every year for four years

  8. Lumbosacral spine radiographic alterations

    Time frame: every year for four years

  9. Clinical Global Impression (CGI) scale

    The CGI scale has two components-the CGI-Severity, which rates illness severity of ill (Score from 1 to 7, where 1 is normal and 7 severely ill) , and the CGI-Improvement, which rates change from the initiation (baseline) of observation (Score from 1 to 7, where 1 is very much improved since the initiation of observation and 7 is very much worse since the initiation of observation)

    Time frame: every year for four years

  10. The Rett Syndrome Behavioural Questionnaire (RSBQ)

    The Rett Syndrome Behaviour Questionnaire (RSBQ) assesses the severity of neurobehavioral problems from the perspective of the caregiver. The RSBQ consists of 45 items of which 38 items are grouped into 8 domains/subscales that reflect the core features (General Mood; Breathing Problems; Hand Behaviors; Repetitive Face Movements; Body Rocking and Expressionless Face; Nighttime Behaviors; Fear/Anxiety; and Walking/Standing) and 7 items are grouped into a subscales classed as "uncategorized" but contribute to the overall total score. Each item is rated on a Likert scale as 0 (behavior "not true"), 1 (behavior "somewhat or sometimes true") or 2 (behavior "often true"), with the total score ranging from 0 to 90 (higher scores indicate increased severity)

    Time frame: every year for four years

Secondary outcomes

  1. Alterations of neurovisual functions

    Time frame: every year for four years

  2. Possibility of applying alternative forms of communication to verbal communication

    Possibility of applying alternative forms of communication to verbal communication (in patients presenting with the absence of expressive language) through the application of the EYE TRACKER device (Tobii Dyanvox) that uses near-infrared lighting in combination with high-definition cameras to project light into the eye and record the direction reflected by the cornea

    Time frame: every year for four years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Feb 2024, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Apr 4, 2024
StartActual
Aug 3, 2020
Primary completionActual
Feb 20, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06346444
Lead sponsor
IRCCS Fondazione Stella Maris
Collaborators
Meyer Children's Hospital IRCCS, Azienda USL Toscana Nord Ovest, University of Dublin, Trinity College
Responsible party
Roberta Battini (Professor, IRCCS Fondazione Stella Maris) — Principal investigator
First posted
Apr 4, 2024
Start date
Aug 3, 2020
Primary completion
Feb 20, 2024
Completion
Dec 31, 2024 (estimated)
Last update
Apr 4, 2024

Study contacts

Roberta Battini
Contact
rbattini@fsm.unipi.it
050886282

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion